IN DB/DB MICE, SGLT2 INHIBITION DOES NOT IMPROVE DIABETIC NEPHROPATHY DESPITE GLYCAEMIC IMPROVEMENTS

被引：0
|
作者：
Gallo, L. A. [1 ]
Ward, M. S. [1 ]
Fotheringham, A. K. [1 ]
Pollock, C. [2 ]
Panchapakesan, U. [2 ]
Forbes, J. M. [1 ]
机构：
[1] Univ Queensland, Mater Res Inst, Woolloongabba, Qld, Australia
[2] Univ Sydney, Kolling Inst Med Res, Sydney, NSW 2006, Australia
来源：
NEPHROLOGY | 2015年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
025
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [1] Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin
    Norgaard, Sisse Andersen
    Briand, Francois
    Sand, Fredrik Wolfhagen
    Galsgaard, Elisabeth Douglas
    Sondergaard, Henrik
    Sorensen, Dorte Bratbo
    Sulpice, Thierry
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 860
  • [2] Luseogliflozin (TS-071), a novel SGLT2 inhibitor, protects against diabetic nephropathy in diabetic db/db mice
    Takiyama, Y.
    Agatsuma, K.
    Yasuda-Kobayashi, M.
    Honjo, J.
    Fujita, Y.
    Yanagimachi, T.
    Kitsunai, H.
    Makino, Y.
    Haneda, M.
    [J]. DIABETOLOGIA, 2013, 56 : S66 - S66
  • [3] The inhibition of diabetic nephropathy by sepia esculenta in db/db mice
    Akagiri, S.
    Ichikawa, H.
    Naito, Y.
    Takagi, T.
    Mizushima, K.
    Okuda, T.
    Handa, O.
    Adachi, S.
    Tsuboi, H.
    Kamada, K.
    Hattori, T.
    Kajikawa, H.
    Suzuki, T.
    Kokura, S.
    Yoshida, N.
    Yoshikawa, T.
    [J]. FREE RADICAL RESEARCH, 2006, 40 : S140 - S140
  • [4] SGLT2 Inhibitor Therapy Improves Blood Glucose but Does Not Prevent Albuminuria nor Glomerular Hypertrophy in Diabetic db/db Mice
    Takiyama, Yumi
    Sera, Toshihiro
    Nakamura, Masanori
    Yanagimachi, Tsuyoshi
    Bessho, Ryoichi
    Fujita, Yukihiro
    Hoshino, Masato
    Uesugi, Kentaro
    Saijo, Yasuaki
    Yagi, Naoto
    Haneda, Masakazu
    [J]. DIABETES, 2017, 66 : A134 - A134
  • [5] SGLT2 Inhibition Prevents the Development of Nephropathy in Diabetic Mice
    Qiu, Liru
    Wang, Xiaoxin
    Hogg-Cornejo, Veronica
    Parker, Cherelle
    Shioshita, Gerald
    Ren, Jimmy
    Liang, Yin
    Levi, Moshe
    [J]. DIABETES, 2013, 62 : A132 - A132
  • [6] Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice
    Okauchi, Seizo
    Shimoda, Masashi
    Obata, Atsushi
    Kimura, Tomohiko
    Hirukawa, Hidenori
    Kohara, Kenji
    Mune, Tomoatsu
    Kaku, Kohei
    Kaneto, Hideaki
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 470 (03) : 772 - 782
  • [7] Protective Effects of SGLT2 Inhibitor Luseogliflozin on Pancreatic Beta Cells in Obese Type 2 Diabetic db/db Mice
    Okauchi, Seizou
    Simoda, Masashi
    Obata, Atsushi
    Kimura, Tomohiko
    Hirukawa, Hidenori
    Kohara, Kenji
    Kaneto, Hideaki
    Kaku, Kohei
    [J]. DIABETES, 2015, 64 : A586 - A586
  • [8] The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice
    Gallo, Linda A.
    Ward, Micheal S.
    Fotheringham, Amelia K.
    Zhuang, Aowen
    Koepsell, Hermann
    Vallon', Volker
    Pollock, Carol
    Panchapakesan, Usha
    Forbes, Josephine M.
    [J]. FASEB JOURNAL, 2016, 30
  • [9] Sodium Glucose Transporter Type 2 (SGLT2) Inhibitor, Empagliflozin, Improves Diastolic Function in Female Diabetic db/db Mice
    Demarco, Vincent G.
    Aroor, Annayya R.
    Nistala, Ravi
    Garro, Mona
    Mayoux, Eric W.
    Whaley-Connell, Adam
    Sowers, James R.
    [J]. DIABETES, 2015, 64 : A552 - A552
  • [10] Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice
    Naito, Y
    Uchiyama, K
    Aoi, W
    Hasegawa, G
    Nakamura, N
    Yoshida, N
    Maoka, T
    Takahashi, J
    Yoshikawa, T
    [J]. BIOFACTORS, 2004, 20 (01) : 49 - 59
12345